BR0114696A - Uso de antiprogestinas para a indução de apoptose em uma célula - Google Patents
Uso de antiprogestinas para a indução de apoptose em uma célulaInfo
- Publication number
- BR0114696A BR0114696A BR0114696-3A BR0114696A BR0114696A BR 0114696 A BR0114696 A BR 0114696A BR 0114696 A BR0114696 A BR 0114696A BR 0114696 A BR0114696 A BR 0114696A
- Authority
- BR
- Brazil
- Prior art keywords
- cell
- antiprogestins
- antiprogestin
- estra
- acetylphenyl
- Prior art date
Links
- 230000000708 anti-progestin effect Effects 0.000 title abstract 6
- 239000003418 antiprogestin Substances 0.000 title abstract 6
- 230000006907 apoptotic process Effects 0.000 title abstract 2
- 230000006698 induction Effects 0.000 title 1
- 210000004027 cell Anatomy 0.000 abstract 3
- -1 4-acetylphenyl Chemical group 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000018199 S phase Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000022131 cell cycle Effects 0.000 abstract 1
- 230000006882 induction of apoptosis Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
"USO DE ANTIPROGESTINAS PARA A INDUçãO DE APOPTOSE EM UMA CéLULA". A presente invenção refere-se a métodos e usos para indução de apoptose em uma célula, em particular uma célula de câncer de mama, através da administração de antiprogestinas, em particular a antiprogestina 11 <225>-(4-acetilfenil)-17<225>-hidróxi-17<244>-(1,1,2,2,2-pentafluor oetil)-estra-4,9-dieno-3-ona ou um derivado farmaceuticamente aceitável ou análogo da mesma. A invenção ainda refere-se a um tratamento de câncer em que um indicador de alto risco é uma quantidade aumentada de células tumorígenas na fase S do ciclo celular, o referido tratamento compreendendo uma antiprogestina, em particular a antiprogestina 11<225>-(4-acetilfenil)-17<244>-hidróxi-17<244>-(1,1,2,2,2-pentaflu oroetil)-estra-4,9-dieno-3-ona ou um derivado farmaceuticamente aceitável ou análogo da mesma.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24099100P | 2000-10-18 | 2000-10-18 | |
| EP00250342 | 2000-10-18 | ||
| PCT/EP2001/012006 WO2002032432A1 (en) | 2000-10-18 | 2001-10-17 | Use of antiprogestins for the induction of apoptosis in a cell |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0114696A true BR0114696A (pt) | 2003-11-18 |
Family
ID=26072952
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0114696-3A BR0114696A (pt) | 2000-10-18 | 2001-10-17 | Uso de antiprogestinas para a indução de apoptose em uma célula |
Country Status (29)
| Country | Link |
|---|---|
| EP (1) | EP1326617B9 (pt) |
| JP (1) | JP2004511523A (pt) |
| KR (1) | KR100668024B1 (pt) |
| CN (1) | CN1209111C (pt) |
| AT (1) | ATE334683T1 (pt) |
| AU (2) | AU2361902A (pt) |
| BG (1) | BG107744A (pt) |
| BR (1) | BR0114696A (pt) |
| CA (1) | CA2423020C (pt) |
| CY (1) | CY1105745T1 (pt) |
| CZ (1) | CZ299823B6 (pt) |
| DE (1) | DE60121980T2 (pt) |
| DK (1) | DK1326617T3 (pt) |
| EA (1) | EA010593B1 (pt) |
| EE (1) | EE200300157A (pt) |
| ES (1) | ES2269492T3 (pt) |
| HK (1) | HK1062273A1 (pt) |
| HR (1) | HRP20030388A2 (pt) |
| HU (1) | HUP0301433A3 (pt) |
| IL (2) | IL154976A0 (pt) |
| MX (1) | MXPA03002955A (pt) |
| NO (1) | NO20031741L (pt) |
| NZ (1) | NZ538347A (pt) |
| PL (1) | PL360157A1 (pt) |
| PT (1) | PT1326617E (pt) |
| SI (1) | SI1326617T1 (pt) |
| SK (1) | SK4702003A3 (pt) |
| UA (1) | UA76729C2 (pt) |
| WO (1) | WO2002032432A1 (pt) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY27301A1 (es) * | 2001-05-25 | 2003-02-28 | Schering Ag | Uso y composiciones de antiprogestinas para el tratamiento de enfermedades de la próstata |
| US20040242551A1 (en) * | 2003-05-28 | 2004-12-02 | Schering Ag | Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases |
| EP2148682A1 (en) * | 2007-04-23 | 2010-02-03 | Bayer Schering Pharma Aktiengesellschaft | Combination of progesterone-receptor antagonist together with a lutein-hormone-releasing hormone agonist and antagonist for use in brca mediated diseases |
| US20080268041A1 (en) * | 2007-04-23 | 2008-10-30 | Jens Hoffmann | Combination of progesterone-receptor antagonist together with none-steroidal antiestrogen for use in brca mediated diseases |
| JP2010524997A (ja) * | 2007-04-23 | 2010-07-22 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | Ｂｒｃａ単独での、又は抗エストロゲン薬を伴った組み合わせ物としての使用のためのプロゲステロン受容体拮抗薬 |
| GB0718167D0 (en) | 2007-09-18 | 2007-10-31 | Cancer Rec Tech Ltd | Cancer marker and therapeutic target |
| KR102009007B1 (ko) * | 2011-10-04 | 2019-08-08 | 인비비스 파마슈티컬스 인코포레이티드 | 항-프로게스틴 민감성 종양을 확인하고 치료하기 위한 방법 및 시스템 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19706061A1 (de) * | 1997-02-07 | 1998-08-13 | Schering Ag | Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette |
-
2001
- 2001-10-17 SK SK470-2003A patent/SK4702003A3/sk not_active Application Discontinuation
- 2001-10-17 BR BR0114696-3A patent/BR0114696A/pt not_active Application Discontinuation
- 2001-10-17 AU AU2361902A patent/AU2361902A/xx active Pending
- 2001-10-17 WO PCT/EP2001/012006 patent/WO2002032432A1/en active IP Right Grant
- 2001-10-17 CN CNB018175694A patent/CN1209111C/zh not_active Expired - Fee Related
- 2001-10-17 DK DK01987669T patent/DK1326617T3/da active
- 2001-10-17 IL IL15497601A patent/IL154976A0/xx active IP Right Grant
- 2001-10-17 EA EA200300479A patent/EA010593B1/ru not_active IP Right Cessation
- 2001-10-17 NZ NZ538347A patent/NZ538347A/en unknown
- 2001-10-17 PT PT01987669T patent/PT1326617E/pt unknown
- 2001-10-17 HU HU0301433A patent/HUP0301433A3/hu unknown
- 2001-10-17 ES ES01987669T patent/ES2269492T3/es not_active Expired - Lifetime
- 2001-10-17 JP JP2002535670A patent/JP2004511523A/ja active Pending
- 2001-10-17 EE EEP200300157A patent/EE200300157A/xx unknown
- 2001-10-17 UA UA2003054311A patent/UA76729C2/uk unknown
- 2001-10-17 AT AT01987669T patent/ATE334683T1/de not_active IP Right Cessation
- 2001-10-17 KR KR1020037005360A patent/KR100668024B1/ko not_active IP Right Cessation
- 2001-10-17 EP EP01987669A patent/EP1326617B9/en not_active Expired - Lifetime
- 2001-10-17 CZ CZ20031073A patent/CZ299823B6/cs not_active IP Right Cessation
- 2001-10-17 AU AU2002223619A patent/AU2002223619B2/en not_active Ceased
- 2001-10-17 CA CA002423020A patent/CA2423020C/en not_active Expired - Fee Related
- 2001-10-17 PL PL01360157A patent/PL360157A1/xx not_active Application Discontinuation
- 2001-10-17 SI SI200130648T patent/SI1326617T1/sl unknown
- 2001-10-17 MX MXPA03002955A patent/MXPA03002955A/es active IP Right Grant
- 2001-10-17 DE DE60121980T patent/DE60121980T2/de not_active Expired - Fee Related
-
2003
- 2003-03-18 IL IL154976A patent/IL154976A/en not_active IP Right Cessation
- 2003-04-15 NO NO20031741A patent/NO20031741L/no not_active Application Discontinuation
- 2003-04-18 BG BG107744A patent/BG107744A/bg unknown
- 2003-05-14 HR HR20030388A patent/HRP20030388A2/hr not_active Application Discontinuation
-
2004
- 2004-07-20 HK HK04105309A patent/HK1062273A1/xx not_active IP Right Cessation
-
2006
- 2006-11-01 CY CY20061101564T patent/CY1105745T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0015974A (pt) | Uso de levetiracetam, composição farmacêutica, uso de uma composição farmacêutica e métodos para tratar um paciente admintstrado com uma quantidade de pelo menos um composto e uma doença e para potenciar seletivamente o efeito terapêutico de um composto | |
| BR0115109A (pt) | Agentes terapêuticos e métodos de uso dos mesmos para a modulação da angiogênese | |
| BR0113927A (pt) | Processos para retardar a recorrência dos sintomas de herpes vìrus | |
| AR052921A1 (es) | Uso de ranolazina para la preparacion de una composicion farmaceutica y composicion farmaceutica | |
| CY1104981T1 (el) | Χρηση των αντιπρογεστερονων για προληψη και αντιμετωπιση των εξαρτωμενων απο ορμονες ασθενειων | |
| BR0010531A (pt) | Composições e usos de et743 para tratamento de câncer | |
| DK1071439T3 (da) | Hybenformuleringer som antiinflammatorisk naturmedicin til lindring/reduktion af symptomer associeret med inflammation og artritis | |
| BR0114696A (pt) | Uso de antiprogestinas para a indução de apoptose em uma célula | |
| BR0316042A (pt) | Kits que contêm compressa para o corpo e dispositivo térmico fixável de modo liberável | |
| BR0313411A (pt) | Uso de reboxetina para o tratamento de ondas de calor | |
| BR0214798A (pt) | Uso de anastrozol ou um sal farmaceuticamente aceitável do mesmo, e, métodos para reduzir a taxa de recorrência de câncer e a taxa de um novo tumor primário contralateral em uma mulher pós-menopausa tendo câncer de mama em estado inicial | |
| ECSP034606A (es) | Uso de antiprogestinas para la induccion de apoptosis en una celula | |
| BR9912816A (pt) | Composição terapêutica à base de flavonóides, tencionada para uso no tratamento de tumores por agentes citotóxicos | |
| BRPI0606724A2 (pt) | preparação farmacêutica para contracepção | |
| IL129267A (en) | Pharmaceutical compositions comprising histamine and/or serotonin for treatment of urinary incontinence | |
| Nanda et al. | Cytotoxic effect of Syzgium aromaticum extract and gemcitabine on human cervical cancer cell line | |
| PL1937274T3 (pl) | Zastosowanie walerianianu estradiolu w połączeniu z dienogestem do doustnej terapii dysfunkcyjnego krwawienia macicznego wraz z doustną antykoncepcją | |
| BR0010070A (pt) | Uso de org 33245, kit contraceptivo, meio combinado para a dosagem de um progestogênio e um antiprogestogênio, e, métodos de contracepção, e de tratamento de sangramento uterino irregular ou de ruptura em uma fêmea utilizando uma preparação somente de progestogênio | |
| YU30103A (sh) | Upotreba antiprogestina za profilaksu i lečenje hormonski zavisnih bolesti | |
| ES2113106T3 (es) | Esteres de 14alfa,15alfa-metilen-estradiol con efecto estrogeno administrables por via oral. | |
| BRMU8400115U (pt) | Calcinha higiênica para mulheres em geral | |
| CO5280075A1 (es) | Drospirenona para terapia de reemplazo de hormonas | |
| BRPI0416019A (pt) | uso de siramesina ou de um seu sal farmaceuticamente aceitável, composição farmacêutica, kit, e, método para o tratamento de cáncer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] |
Free format text: DE ACORDO COM O ART.34 "II" DA LPI (LEI 9279, DE 14/05/96), O EXAME FICA SUSPENSO PARA QUE O REQUERENTE APRESENTE DOCUMENTOS NECESSARIOS A REGULARIZACAO DO PROCESSO E EXAME DO PEDIDO. |
|
| B11E | Dismissal acc. art. 34 of ipl - requirements for examination incomplete | ||
| B11T | Dismissal of application maintained [chapter 11.20 patent gazette] |